BHV-2100, a First-in-Class TRPM3 Antagonist in Development for the Treatment of Migraine (P7-12.009)
Describe the rationale and design of a pivotal Phase 2 clinical trial of BHV-2100 for acute treatment of migraine.
Authors
- Richard B. Lipton (ORCID: https://orcid.org/0000-0003-2652-2897)
- Christopher Jensen
- Irfan Qureshi (ORCID: https://orcid.org/0000-0002-0572-0993)
- Joris Vriens (ORCID: https://orcid.org/0000-0002-2502-0409)
- Andrew T. Lucas (ORCID: https://orcid.org/0000-0001-8678-5985)
- Volkan Granit (ORCID: https://orcid.org/0000-0002-6519-7225)
- Thomas Voets (ORCID: https://orcid.org/0000-0001-5526-5821)
- Beth Morris (ORCID: https://orcid.org/0009-0006-4347-2042)
- Beth Emerson (ORCID: https://orcid.org/0000-0003-3646-0466)
- Vladimir Coric
- Anne Pieters
Institutions
- Albert Einstein College of Medicine (US)
- Biohaven Pharmaceuticals (United States) (US)
- VIB-KU Leuven Center for Brain & Disease Research (BE)
- KU Leuven (BE)
Publication Details
- Journal
- Neurology
- Published
- 2025-04-07
- DOI
- https://doi.org/10.1212/wnl.0000000000211319
- Citations
- 3
- Primary Topic
- Migraine and Headache Studies
- Type
- article
- Field-Weighted Citation Impact
- 4.41